Zhewitra
Zhewitra Price range: $ 28,00 through $ 149,00
Back to products
Zhewitra Soft
Zhewitra Soft Price range: $ 54,00 through $ 210,00

Zhewitra Oral Jelly

Price range: $ 61,00 through $ 110,00

Zhewitra Oral Jelly is an innovative and effective treatment designed specifically for men experiencing erectile dysfunction. Containing Vardenafil as its active ingredient, this medication works by increasing blood flow to the pelvic area to support a firm and lasting erection. The convenient jelly form is perfect for those who have difficulty swallowing traditional pills and offers a faster onset of action compared to standard tablets. Users can enjoy improved sexual performance and restored confidence with a formula that is absorbed quickly into the bloodstream. Available in various pleasant flavors, Zhewitra Oral Jelly provides a discreet and reliable solution for enhancing your intimate health and overall satisfaction.

Active substance: Vardenafil
SKU: Zhewitra Oral Jelly Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Zhewitra Oral Jelly belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. Formulated as a liquid-gel oral jelly containing the active pharmaceutical ingredient vardenafil, this agent is indicated for the management of erectile dysfunction in adult males. The oral jelly preparation offers an alternative oral dosage form to conventional solid tablets.

In the United States, vardenafil-containing medications are subject to prescription-only regulation and must be dispensed in accordance with federal and state laws following a comprehensive evaluation by a qualified healthcare professional. Proper administration requires an accurate diagnostic assessment of underlying cardiovascular status and erectile health prior to initiating therapy.

Clinical Profile and Pharmacological Properties

Basic Information

Drug Name Zhewitra Oral Jelly
Active Ingredient (INN) Vardenafil hydrochloride
Therapeutic Class Phosphodiesterase Type 5 (PDE5) Inhibitor
Dosage Form Oral Jelly (Sachet)
Route of Administration Oral
Prescription Status Dispensed in accordance with applicable federal and state regulations

How the drug works

The pharmacological activity of vardenafil stems from its potent and selective inhibition of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). During physiological sexual stimulation, nitric oxide is released from nerve terminals and endothelial cells in the corpus cavernosum of the penis. Nitric oxide activates the enzyme guanylate cyclase, resulting in increased synthesis of cGMP. Elevated cGMP concentrations induce smooth muscle relaxation in the penile arteries and cavernous tissue, enabling increased arterial blood inflow and subsequent penile erection. PDE5 is the primary enzyme responsible for the degradation of cGMP in the cavernous tissue. By selectively inhibiting PDE5, vardenafil prevents cGMP breakdown, thereby enhancing the natural hemodynamic response to sexual stimulation.

What it’s used for

Zhewitra Oral Jelly is clinically indicated for the treatment of erectile dysfunction (ED) in adult men, a condition characterized by the persistent or recurrent inability to attain or maintain a penile erection sufficient for satisfactory sexual performance. Effective therapeutic response requires intact sensory and neural pathways, as the agent does not exert a direct relaxant effect on isolated human corpus cavernosum in the absence of sexual stimulation. The medication is not indicated for use in pediatric populations, nor is it approved for use in women. Off-label use for other vascular conditions must be strictly supervised by a licensed clinician.

What happens in the body

Pharmacokinetic analysis indicates that vardenafil is rapidly absorbed following oral administration. Maximum observed plasma concentrations are generally attained within 30 to 120 minutes in the fasted state. The absolute bioavailability of oral vardenafil is approximately 15%, primarily due to extensive first-pass hepatic metabolism. Vardenafil is bound to human plasma proteins at approximately 95%, and this binding is reversible and independent of total drug concentrations. Hepatic metabolism is predominantly mediated by the cytochrome P450 isoenzyme CYP3A4, with minor contributions from CYP3A5 and CYP2C isoforms. The major circulating metabolite (M1) results from de-ethylation of vardenafil and exhibits approximately 28% of the parent compound’s potency against PDE5. The terminal elimination half-life of vardenafil and its M1 metabolite ranges from approximately 4 to 5 hours.

Administration, Safety, and Precautions

Dosing schedule

The administration of Zhewitra Oral Jelly must follow specific medical instructions provided by a prescribing healthcare provider. The recommended starting dose is determined based on individual clinical efficacy, patient tolerance, and underlying co-morbidities. The jelly is consumed directly from the sachet or emptied onto a spoon shortly before anticipated sexual activity. Only one dose should be administered within a 24-hour period. Dosage adjustments may be necessary for patients with moderate hepatic impairment or severe renal impairment, as well as those concurrently taking specific metabolic inhibitors.

What not to combine

Vardenafil exhibits significant interactions with several classes of pharmaceutical agents. Concurrent administration with organic nitrates (such as nitroglycerin, isosorbide mononitrate, or isosorbide dinitrate) or nitric oxide donors is strictly contraindicated, as PDE5 inhibition can severely potentiate the hypotensive effects of nitrates, leading to dangerous drops in blood pressure. Simultaneous use with guanylate cyclase stimulators, such as riociguat, is also contraindicated. Alpha-blockers prescribed for hypertension or benign prostatic hyperplasia may cause additive blood pressure lowering when co-administered with PDE5 inhibitors; careful dose titration and clinical stability must be established prior to combination therapy. Potent CYP3A4 inhibitors (including ketoconazole, itraconazole, ritonavir, and indinavir) significantly increase systemic exposure to vardenafil, requiring substantial dose reduction or complete avoidance.

Adverse reactions

Clinical evaluation reveals that adverse reactions associated with vardenafil are predominantly mild to moderate in intensity and transient in nature. The most commonly reported side effects include headache, facial flushing, nasal congestion, dyspepsia, nausea, and dizziness. Less common adverse events encompass visual disturbances (such as altered color perception, increased sensitivity to light, or blurred vision), back pain, and myalgia. In rare cases, cardiovascular events including transient ischemic attacks, palpitations, or tachycardia have been reported. Patients experiencing persistent or intolerable side effects should consult their healthcare provider for clinical evaluation.

Important precautions

Prior to initiating therapy with Zhewitra Oral Jelly, physicians must assess the cardiovascular status of the patient, as sexual activity carries an inherent cardiac risk for individuals with pre-existing cardiovascular disease. Vardenafil is not recommended for patients with unstable angina, recent myocardial infarction, severe heart failure, uncontrolled arrhythmias, or severe hypotension. Caution is advised in patients with anatomical penile deformations (such as Peyronie’s disease) or conditions predisposing to priapism (such as sickle cell anemia, multiple myeloma, or leukemia). Rare cases of sudden decrease or loss of vision attributed to non-arteritic anterior ischemic optic neuropathy (NAION) and sudden hearing loss have been documented with PDE5 inhibitors. Patients with a history of congenital QT prolongation or those taking antiarrhythmic medications should be monitored closely due to potential electrophysiological impacts.

Red flags

Immediate emergency medical intervention is required if a patient experiences any severe or life-threatening adverse reactions. Critical warning signs include an erection lasting longer than 4 hours (priapism), which can result in irreversible damage to penile tissue if untreated. Sudden vision loss in one or both eyes, sudden decrease or loss of hearing, severe chest pain radiating to the jaw or left arm, severe dizziness, syncope, or signs of a serious allergic reaction (including swelling of the face, lips, tongue, or throat, and difficulty breathing) necessitate urgent medical evaluation in an emergency care facility.

What to avoid while taking it

Dietary factors can influence the absorption and pharmacological profile of vardenafil. While Zhewitra Oral Jelly may be administered with or without food, the consumption of high-fat meals prior to ingestion may delay the onset of therapeutic effect by slowing the rate of gastrointestinal absorption. Concomitant intake of substantial quantities of alcohol should be avoided, as ethanol possesses intrinsic vasodilatory properties that may exacerbate PDE5 inhibitor-induced hypotension, dizziness, and heart rate elevation. Furthermore, grapefruit juice should be avoided because it inhibits CYP3A4 metabolism, potentially increasing plasma levels of vardenafil and escalating the risk of adverse events.

Storage and expiration

Zhewitra Oral Jelly sachets must be stored at room temperature, ideally between 59°F and 86°F (15°C to 30°C), protected from excessive heat, moisture, and direct sunlight. The sachets should remain sealed in their original packaging until immediately prior to use. Storage in high-humidity environments such as bathrooms should be avoided. Keep this medication out of the reach of children and pets. Do not use the gel after the expiration date clearly printed on the outer packaging and individual sachet.

Common Questions

How quickly does the oral jelly formulation take effect compared to standard tablets?

The liquid-gel matrix of oral jelly preparations allows for rapid dissolution in the oral cavity and digestive tract. Onset of action typically occurs within 30 to 60 minutes after ingestion, provided the medication is taken on an empty or light-meal stomach. Individual response times may vary depending on metabolic factors and concurrent food consumption.

What should be done if a scheduled or planned dose is missed?

Zhewitra Oral Jelly is administered on an as-needed basis prior to sexual activity, rather than on a fixed daily dosing schedule. Consequently, missing a dose is not clinically problematic. Patients should never take a double dose or consume more than one sachet within a 24-hour timeframe to compensate for an unconsumed dose.

Is it safe to drive or operate machinery after taking this medication?

Because vardenafil can cause adverse effects such as dizziness, lightheadedness, or visual disturbances, patients should observe their individual physical response to the medication before driving or operating dangerous machinery. If visual changes or dizziness occur, hazardous tasks should be avoided until symptoms completely resolve.

Why are nitrates strictly prohibited with vardenafil?

Nitrates and PDE5 inhibitors both act to induce vascular smooth muscle relaxation through the nitric oxide-cGMP pathway. When combined, their actions synergize, causing severe, unpredictable drops in systemic blood pressure. This severe hypotension can result in syncope, myocardial ischemia, or stroke.

Can this medication be used regularly on a daily basis?

Zhewitra Oral Jelly is generally intended for episodic, as-needed use before sexual activity. Continuous daily administration is not standard for this specific dosage form unless explicitly recommended and monitored by a prescribing clinician based on individual therapeutic goals.

In accordance with FDA requirements.

Information on this page is for reference and does not replace an assessment by a licensed healthcare professional.

Additional information
Dosage

20 mg

Package

20 sachets

,

60 sachets

Ενεργός Ουσία